Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments DOI Creative Commons
Xinyu Luo,

Yufan Lv,

Jinsai Yang

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Dec. 19, 2024

Traditional immunotherapies mainly focus on αβ T cell-based strategies, which depend MHC-mediated antigen recognition. However, this approach poses significant challenges in treating recurrent tumors, as immune escape mechanisms are widespread. γδ cells, with their ability for MHC-independent presentation, offer a promising alternative that could potentially overcome limitations observed traditional immunotherapies. These cells play role tumor surveillance through unique mechanism of recognition and synergistic interactions other effector cells. In review, we will discuss the biological properties Vδ1 Vδ2 subsets immunomodulatory within microenvironment, most recent clinical advances related immunotherapies, including cell engaging strategies adoptive therapy.

Language: Английский

Gamma delta T cells and their immunotherapeutic potential in cancer DOI Creative Commons

Stephen G. Cieslak,

Reza Shahbazi

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: March 28, 2025

Language: Английский

Citations

0
Study on the mechanism of liver cancer immune escape mediated by MINDY1 through regulation of PD-L1 ubiquitination level DOI Creative Commons
Xingchao Song, Wenjin Li, Chunyan Tian

et al.

Biomolecules and Biomedicine, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 31, 2024

The novel deubiquitinase enzyme, motif interacting with ubiquitin-containing DUB family-1 (MINDY1), is highly expressed in liver cancer tissues and plays a crucial role maintaining the stemness of cells. Programmed death ligand-1 (PD-L1) an immunosuppressive molecule overexpressed by tumour potential MINDY1 inhibiting cells deubiquitinating PD-L1 has not yet been reported. To investigate mechanism which mediates immune escape through regulation ubiquitination, we examined expression levels adjacent from 50 hepatocellular carcinoma (HCC) patients using protein imprinting immunohistochemistry. We analyzed relationship between their correlation 5-year tumor-free survival rates patients. Subsequently, was knocked down Huh7 small interfering RNA (siRNA) interference or upregulated transfection overexpression plasmid. effects knockdown on proliferation, apoptosis, migration, invasion HCC cells, as well binding were assessed. significantly lower both high group (χ2 = 4.919 13.158, respectively). A significant difference observed low groups (χ2= 27.415). found to directly interact PD-L1, gene promoting ubiquitination ubiquitination. All comparisons yielded statistically results (P < 0.05). In conclusion, inhibits malignant progression mediating escape.

Language: Английский

Citations

3
Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma DOI Open Access
Stavros P. Papadakos, Elena Chatzikalil,

Georgios Vakadaris

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2609 - 2609

Published: July 22, 2024

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and presents a continuously growing incidence high mortality rates worldwide. Besides advances in diagnosis promising results of pre-clinical studies, established curative therapeutic options for HCC are not currently available. Recent progress understanding tumor microenvironment (TME) interactions has turned scientific interest to immunotherapy, revolutionizing treatment patients with advanced HCC. However, limited number who benefit from current immunotherapeutic creates need explore novel targets associated improved patient response potentially establish them as part combinatorial options. Glucocorticoid-induced TNFR-related protein (GITR) belongs TNFR superfamily (TNFRSF) promotes CD8+ CD4+ effector T-cell function simultaneous inhibition Tregs function, when activated by its ligand, GITRL. GITR considered potential immunotherapy target various kinds neoplasms, especially concomitant use programmed cell-death protein-1 (PD-1) blockade. Regarding disease, expression progenitor cells been observed, impaired hepatocyte differentiation, decreased cell-mediated regeneration. Considering real-world data proving anti-tumor effect recently published evidence models involvement pre-cancerous idea inclusion theoretically arises. In this review, we aim summarize supporting targeting GITR/GITRL signaling strategy

Language: Английский

Citations

2
Strategies to enhance the response of liver cancer to pharmacological treatments DOI
José J.G. Marı́n, Rocı́o I.R. Macı́as, Maitane Asensio

et al.

AJP Cell Physiology, Journal Year: 2024, Volume and Issue: 327(1), P. C11 - C33

Published: May 6, 2024

In contrast to other types of cancers, there is no available efficient pharmacological treatment improve the outcomes patients suffering from major primary liver i.e., hepatocellular carcinoma and cholangiocarcinoma. This dismal situation partly due existence in these tumors many different synergistic mechanisms resistance, accounting for lack response patients, not only classical chemotherapy but also more modern agents based on inhibition tyrosine kinase receptors (TKIs) stimulation immune against tumor using checkpoint inhibitors (ICIs). review summarizes efforts develop strategies overcome this severe limitation, including searching novel drugs derived synthetic, semisynthetic, or natural products with vectorial properties therapeutic targets increase drug uptake reduce export cancer cells. Besides, immunotherapy a promising line research that already starting be implemented clinical practice. Although less successful than foreseen future strategy treating cancers considerable. Similarly, epigenetic highly promising. Many “epidrugs,” able act “writer,” “reader,” “eraser” players, are currently being evaluated preclinical studies. Finally, gene therapy broad field fight chemoresistance, impressive advances recently achieved manipulation. sum, although present still dismal, reason hope non-too-distant future.

Language: Английский

Citations

1
Genotype–phenotype correlation in IBD: unveiling putative inhibitors for IL10RA and IRF5 variants—an in silico analysis DOI

Treesa Bency Evthonis,

Gopinath Samykannu,

Jeyakumar Natarajan

et al.

Journal of Proteins and Proteomics, Journal Year: 2024, Volume and Issue: 15(3), P. 509 - 522

Published: June 26, 2024

Language: Английский

Citations

1
Research trends of cellular immunotherapy for primary liver cancer: A bibliometric analysis DOI Creative Commons

Xiang’an Wu,

Yuxin Wang, Xiao Liu

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Nov. 13, 2024

Cellular immunotherapy has shown considerable potential for the treatment of primary liver cancer (PLC), particularly hepatocellular carcinoma (HCC), although it is in early stages development. This study used bibliometric methods to delineate evolution research on cellular PLC. Data were sourced from Web Science Core Collection (WoSCC) April 22, 2024. Using "Bibliometrix" R package, we examined features, collaboration frequency between countries, and article output journals. Furthermore, employed VOSviewer coauthorship analysis visualization CiteSpace assess keyword co-occurrence, as well spotlight keywords references with strongest citation bursts. Our encompassed 492 publications focused PLC immunotherapy, pinpointed China, Japan, USA foremost contributing nations identified "Cancer Immunology Immunotherapy" journal most contributions this area. Sun Yat-sen University emerged institution significant output, Li Zonghai authored greatest number leading articles. Prominent that displayed a notable burst later years included "chimeric antigen receptor," "combination therapy", "CAR-T cells," "TCR-T "liver transplantation." outlined foundational knowledge framework, surveyed over three decades PLC, revealed key players trends, thereby offering thorough understanding field, especially relation HCC.

Language: Английский

Citations

1
Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments DOI Creative Commons
Xinyu Luo,

Yufan Lv,

Jinsai Yang

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Dec. 19, 2024

Traditional immunotherapies mainly focus on αβ T cell-based strategies, which depend MHC-mediated antigen recognition. However, this approach poses significant challenges in treating recurrent tumors, as immune escape mechanisms are widespread. γδ cells, with their ability for MHC-independent presentation, offer a promising alternative that could potentially overcome limitations observed traditional immunotherapies. These cells play role tumor surveillance through unique mechanism of recognition and synergistic interactions other effector cells. In review, we will discuss the biological properties Vδ1 Vδ2 subsets immunomodulatory within microenvironment, most recent clinical advances related immunotherapies, including cell engaging strategies adoptive therapy.

Language: Английский

Citations

0